Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis

Autores
Cuppari, Anahi Fernandez; Sanchez, Vanesa; Ledesma, Bibiana A; Frank, Fernanda M.; Goldman, Alejandra; Angel, Sergio O.; Martín, Valentina
Año de publicación
2008
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Cuppari, Anahi Fernandez. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
Fil: Sanchez, Vanesa. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
Fil: Ledesma, Bibiana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.
Fil: Frank, Fernanda M. Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, and Facultad de Farmacia y Bioquímica, IDEHU, CONICET Universidad de Buenos Aires, Buenos Aires; Argentina
Fil: Goldman, Alejandra. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires, Argentina.
Fil: Angel, Sergio O. Laboratorio de Parasitología Molecular, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina.
Fil: Martin, Valentina. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
The Toxoplasma gondii serin protease inhibitor-1 (TgPI-1) is a dense granule antigen that showed to specifically inhibit trypsin, chymotrypsin and neutrophil elastase, suggesting a possible modulatory role during the parasite invasion process and on the development of the innate immune response. To study the immune-protective value of TgPI-1, C3H/HeN mice were immunized with a recombinant form of the antigen rTgPI-1 combined with alum. All immunized mice produced specific anti-rTgPI-1 immunoglobulins, with high IgG antibody titers and a mixed IgG(1)/IgG(2a) response, with predominance of IgG(1) production. The cellular immune response was associated with the production of IFN-gamma and IL-10 cytokines. Vaccinated mice displayed significant protection against an oral challenge either after a lethal infection with Me49 cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load) compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune response providing partial protection against both T. gondii acute and chronic infection, so it would be a good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite antigens.
Fuente
Vaccine 2008; 26(39):5040-5.
Materia
Toxoplasma
Toxoplasmosis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
none
Repositorio
Sistema de Gestión del Conocimiento ANLIS MALBRÁN
Institución
Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
OAI Identificador
oai:sgc.anlis.gob.ar:Publications/123456789/2253
Acceder
id SGCANLIS_911e5293671dc68fe1dadd56d45afb46
oai_identifier_str oai:sgc.anlis.gob.ar:Publications/123456789/2253
network_acronym_str SGCANLIS
repository_id_str a
network_name_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
spelling Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosisCuppari, Anahi FernandezSanchez, VanesaLedesma, Bibiana AFrank, Fernanda M.Goldman, AlejandraAngel, Sergio O.Martín, ValentinaToxoplasmaToxoplasmosisFil: Cuppari, Anahi Fernandez. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.Fil: Sanchez, Vanesa. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.Fil: Ledesma, Bibiana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.Fil: Frank, Fernanda M. Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, and Facultad de Farmacia y Bioquímica, IDEHU, CONICET Universidad de Buenos Aires, Buenos Aires; ArgentinaFil: Goldman, Alejandra. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires, Argentina.Fil: Angel, Sergio O. Laboratorio de Parasitología Molecular, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina.Fil: Martin, Valentina. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.The Toxoplasma gondii serin protease inhibitor-1 (TgPI-1) is a dense granule antigen that showed to specifically inhibit trypsin, chymotrypsin and neutrophil elastase, suggesting a possible modulatory role during the parasite invasion process and on the development of the innate immune response. To study the immune-protective value of TgPI-1, C3H/HeN mice were immunized with a recombinant form of the antigen rTgPI-1 combined with alum. All immunized mice produced specific anti-rTgPI-1 immunoglobulins, with high IgG antibody titers and a mixed IgG(1)/IgG(2a) response, with predominance of IgG(1) production. The cellular immune response was associated with the production of IFN-gamma and IL-10 cytokines. Vaccinated mice displayed significant protection against an oral challenge either after a lethal infection with Me49 cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load) compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune response providing partial protection against both T. gondii acute and chronic infection, so it would be a good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite antigens.Elsevier2008-09-15info:ar-repo/semantics/articuloinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdf0264-410Xhttp://sgc.anlis.gob.ar/handle/123456789/225310.1016/j.vaccine.2008.07.031Vaccine 2008; 26(39):5040-5.reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁNinstname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"instacron:ANLISVaccinenoneinfo:eu-repo/semantics/openAccesseng2025-09-04T11:18:22Zoai:sgc.anlis.gob.ar:Publications/123456789/2253Institucionalhttp://sgc.anlis.gob.ar/Organismo científico-tecnológicoNo correspondehttp://sgc.anlis.gob.ar/oai/biblioteca@anlis.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:a2025-09-04 11:18:23.067Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"false
dc.title.none.fl_str_mv Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
title Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
spellingShingle Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
Cuppari, Anahi Fernandez
Toxoplasma
Toxoplasmosis
title_short Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
title_full Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
title_fullStr Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
title_full_unstemmed Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
title_sort Toxoplasma gondii protease inhibitor-1 (TgPI-1) is a novel vaccine candidate against toxoplasmosis
dc.creator.none.fl_str_mv Cuppari, Anahi Fernandez
Sanchez, Vanesa
Ledesma, Bibiana A
Frank, Fernanda M.
Goldman, Alejandra
Angel, Sergio O.
Martín, Valentina
author Cuppari, Anahi Fernandez
author_facet Cuppari, Anahi Fernandez
Sanchez, Vanesa
Ledesma, Bibiana A
Frank, Fernanda M.
Goldman, Alejandra
Angel, Sergio O.
Martín, Valentina
author_role author
author2 Sanchez, Vanesa
Ledesma, Bibiana A
Frank, Fernanda M.
Goldman, Alejandra
Angel, Sergio O.
Martín, Valentina
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Toxoplasma
Toxoplasmosis
topic Toxoplasma
Toxoplasmosis
dc.description.none.fl_txt_mv Fil: Cuppari, Anahi Fernandez. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
Fil: Sanchez, Vanesa. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
Fil: Ledesma, Bibiana. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas. Departamento de Parasitología; Argentina.
Fil: Frank, Fernanda M. Departamento de Microbiología, Parasitología e Inmunología, Facultad de Medicina, and Facultad de Farmacia y Bioquímica, IDEHU, CONICET Universidad de Buenos Aires, Buenos Aires; Argentina
Fil: Goldman, Alejandra. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires, Argentina.
Fil: Angel, Sergio O. Laboratorio de Parasitología Molecular, IIB-INTECH, CONICET-UNSAM, Chascomús, Provincia de Buenos Aires, Argentina.
Fil: Martin, Valentina. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
The Toxoplasma gondii serin protease inhibitor-1 (TgPI-1) is a dense granule antigen that showed to specifically inhibit trypsin, chymotrypsin and neutrophil elastase, suggesting a possible modulatory role during the parasite invasion process and on the development of the innate immune response. To study the immune-protective value of TgPI-1, C3H/HeN mice were immunized with a recombinant form of the antigen rTgPI-1 combined with alum. All immunized mice produced specific anti-rTgPI-1 immunoglobulins, with high IgG antibody titers and a mixed IgG(1)/IgG(2a) response, with predominance of IgG(1) production. The cellular immune response was associated with the production of IFN-gamma and IL-10 cytokines. Vaccinated mice displayed significant protection against an oral challenge either after a lethal infection with Me49 cysts (90% survival vs. 50%) and also after a non-lethal infection (58% reduction in brain parasite load) compared to the non-vaccinated control group. In conclusion, rTgPI-1 elicits a strong specific immune response providing partial protection against both T. gondii acute and chronic infection, so it would be a good candidate in a vaccine against toxoplasmosis, which could be combined with other relevant parasite antigens.
description Fil: Cuppari, Anahi Fernandez. Laboratorio de Inmunología, Centro de Salud y Medio Ambiente, E.C.y T., Universidad de Gral. San Martín, Provincia de Buenos Aires; Argentina.
publishDate 2008
dc.date.none.fl_str_mv 2008-09-15
dc.type.none.fl_str_mv info:ar-repo/semantics/articulo
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv 0264-410X
http://sgc.anlis.gob.ar/handle/123456789/2253
10.1016/j.vaccine.2008.07.031
identifier_str_mv 0264-410X
10.1016/j.vaccine.2008.07.031
url http://sgc.anlis.gob.ar/handle/123456789/2253
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Vaccine
dc.rights.none.fl_str_mv none
info:eu-repo/semantics/openAccess
rights_invalid_str_mv none
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv Vaccine 2008; 26(39):5040-5.
reponame:Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname:Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron:ANLIS
reponame_str Sistema de Gestión del Conocimiento ANLIS MALBRÁN
collection Sistema de Gestión del Conocimiento ANLIS MALBRÁN
instname_str Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
instacron_str ANLIS
institution ANLIS
repository.name.fl_str_mv Sistema de Gestión del Conocimiento ANLIS MALBRÁN - Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"
repository.mail.fl_str_mv biblioteca@anlis.gov.ar
_version_ 1842344424718204928
score 12.623145

Publicaciones similares